Ipilimumab Combination Dosing: Less is More
Abstract
Ipilimumab with and without anti–Programmed Death 1 (PD-1) improved overall survival (OS) in melanoma. Despite this, the optimal dose and therapeutic mechanism of ipilimumab in patients remains unclear. KEYNOTE-029 and other studies suggest that low-dose ipilimumab with anti-PD1 maintains efficacy while decreasing toxicity, emphasizing T-cell trafficking and reinvigoration as likely mechanisms.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 02, 2021
- Source ID
- 10.1158/1078-0432.ccr-21-2406
Entities
People
- Jason J Luke
- Max Jameson-lee
Organizations
- National Institutes of Health
- United States Department of Defense
- University of Pittsburgh